In our recent Review (The different roles of ER subtypes in cancer biology and therapy. Nature Rev. Cancer 11, 597–608 (2011))1, we address the mechanisms that regulate the cellular levels of oestrogen receptors (ERs). We thank Yu et al. for their correspondence on our article2, in which we focus on the role of the transcriptional regulation of ERs, including the hypermethylation of ER promoters, the post-transcriptional regulation by microRNAs and proteasome-mediated degradation of ERs. Alteration of ER levels by these mechanisms has been reported to be a common event in a number of cancers (such as in breast, prostate, colon and gynaecological cancers). In addition, the contribution of these mechanisms to the regulation of the ER levels in cancer has been validated in different systems (specimens from human subjects, and animal and cell-based studies) by using different methods3,4,5,6.
In their correspondence, Yu et al. indicate that the mechanism of ESR1 amplification, which is not mentioned in our Review, deserves to be discussed when illustrating the mechanisms of ERα upregulation. To support this, they discuss the results from several studies, including that of Holst et al.7, which reported that amplification of ESR1, as detected by fluorescence in situ hybridization (FISH), occurs in a substantial proportion of breast cancers (20.6%). Holst et al.7 also found that ESR1 amplification predicts a better response to tamoxifen therapy in a subset of individuals with breast cancer7. However, several groups have challenged these results, and, by using a variety of methods including comparative genomic hybridization (CGH), FISH and quantitative PCR, have shown a low frequency of ESR1 amplification in breast cancers (two studies reported ESR1 amplification in 1%, and less than 1%, of breast cancers)8,9,10,11. Interestingly, in one of these studies, ESR1 amplification did not show any significant correlation with ERα expression10. More recent studies have produced contradictory data with regard to the frequency of ESR1 amplification (different ESR1 amplification frequencies have been detected with different techniques) and have questioned its clinical significance for breast and other types of cancer12. Consistent with the data from the majority of the previous studies, Moelans et al.13 have recently shown that ESR1 amplification is a rare event in breast cancer. In contrast to the findings by Holst et al.7, Nielsen et al.14 suggested that ESR1 amplification is associated with increased tamoxifen resistance in ERα-positive breast cancers. Together, these results, which have been derived from several institutions, have not validated previous findings of high-frequency ESR1 amplification in cancer7 and conclude that ESR1 amplification in breast cancer is an uncommon event of unknown clinical importance.
Taking these data into consideration in our Review, we avoided including ESR1 amplification in the list tabulating important and well-validated mechanisms that are responsible for changes in ER levels and activities in cancer cells and tissues.
References
Thomas, C. & Gustafsson, J.-Å. The different roles of ER subtypes in cancer biology and therapy. Nature Rev. Cancer 11, 597–608 (2011).
Yu. et al. ESR1 gene amplification: another mechanism regulating the cellular levels of ERα. Nature Rev. Cancer (doi:10.1038/nrc3093-c1).
Pan, X. et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nature Med. 17, 708–714 (2011).
Giamas, G. et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Med. 17, 715–719 (2011).
Al-Nakhle, H. et al. Estrogen receptor β1 expression is regulated by miR-92 in breast cancer. Cancer Res. 70, 4778–4784 (2010).
Zhu, X. et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164, 2003–2012 (2004).
Holst, F. et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genet. 39, 655–660 (2007).
Brown, L. A. et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 806–812 (2008).
Horlings, H. M. et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 807–812 (2008).
Reis-Filho, J. S. et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809–812 (2008).
Vincent-Salomon, A., Raynal, V., Lucchesi, C., Gruel, N. & Delattre, O. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809–812 (2008).
Tan, D. S., Lambros, M. B., Marchio, C. & Reis-Filho, J. S. ESR1 amplification in endometrial carcinomas: hope or hyperbole? J. Path. 216, 271–274 (2008).
Moelans, C. B. et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cell Oncol. (Dordr) (doi:10.1007/s13402-011-0045-5).
Nielsen, K. V. et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res.Treat 127, 345–355 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.-A.G. is a consultant with Karo Bio AB and BioNovo. C.T. declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Thomas, C., Gustafsson, JÅ. Not enough evidence to include ESR1 amplification. Nat Rev Cancer 11, 823 (2011). https://doi.org/10.1038/nrc3093-c2
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3093-c2
This article is cited by
-
On the evidence for ESR1 amplification in breast cancer
Nature Reviews Cancer (2012)